NFE2L2 and ovarian carcinoma: The NRF2/HO-1 axis is reportedly activated in neuroblastoma after bortezomib treatment [29], in cisplatin-treated ovarian carcinoma cells [30], and in doxorubicin-resistant breast cancer cells [31].